Purpura fulminans caused by group A β-hemolytic Streptococcus sepsis

Journal of Pediatrics

Volumn 137, Issue 4, 2000, Pages 562-567

  Dhodapkar, Kavita ^b   Corbacioglu, Selim ^b   Chang, Mary Wu ^b   Karpatkin, Margaret ^b   DiMichele, Donna ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFOTAXIME; HEPARIN; TISSUE PLASMINOGEN ACTIVATOR;

ANAMNESIS; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CHILD; CLINICAL EXAMINATION; FULMINATING PURPURA; HEPARINIZATION; HUMAN; INFANT; MALE; PRIORITY JOURNAL; SEPSIS; STREPTOCOCCUS GROUP A;

EID: 0033754095     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1067/mpd.2000.109926     Document Type: Article

References (37)

1. Adcock DM, Brozna J, Madar RA. Proposed classification and pathologic mechanisms of purpura fulminans and skin necrosis. Semin Thromb Hemost 1990;16:333-40.
2. Francis RB Jr. Acquired purpura fulminans. Semin Thromb Hemost 1990; 16:310-25.
3. Bergmann F, Hoyer PF, D'Angelo SV, Mazzola G, Oestereich C, Barthels M, et al. Severe autoimmune protein S deficiency in a boy with idiopathic purpura fulminans. Br J Haematol 1995; 89:610-4.
4. Mitchell CA, Rowell JA, Hau L, Young JP, Salem HH. A fatal thrombotic disorder associated with an acquired inhibitor of protein C. N Engl J Med 1987;317:1638-42.
5. Marlar RA, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost 1990;16:299-309.
6. Mahasandana C, Suvatte V, Marlar RA, Manco-Johnson MJ, Jacobson LJ, Hathaway WE. Neonatal purpura fulminans associated with homozygous protein S deficiency [letter]. Lancet 1990;335:61-2.
7. Rintala E, Seppala OP, Kotilainen P, Pettila V, Rasi V. Protein C in the treatment of coagulopathy in meningococcal disease [see comments]. Crit Care Med 1998;26:965-8.
8. Girardin E, Grau GE, Dayer JM, Roux-Lombard P, Lambert PH. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med 1988;319:397-400.
9. Darmstadt GL. Acute infectious purpura fulminans: pathogenesis and medical management. Pediatr Dermatol 1998;15:169-83.
10. Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987;79:124-30.
11. Pralong G, Calandra T, Glauser MP, Schellekens J, Verhoef J, Bachmann F, et al. Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost 1989; 61:459-62.
12. Smith OP, White B. Infectious purpura fulminans: diagnosis and treatment. Br J Haematol 1999;104:202-7.
13. Keeley SR, Matthews NT, Buist M. Tissue plasminogen activator for gangrene in fulminant meningococcaemia [letter]. Lancet 1991;337:1359.
14. Aiuto LT, Barone SR, Cohen PS, Boxer RA. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans. Crit Care Med 1997;25:1079-82.
15. Zenz W, Muntean W, Gallistl S, Zobel G, Grubbauer HM. Recombinant tissue plasminogen activator treatment in two infants with fulminant meningococcemia. Pediatrics 1995;96:44-8.
16. Chenaille PJ, Horowitz ME. Purpura fulminans. A case for heparin therapy. Clin Pediatr (Phila) 1989;28:95-8.
17. Gerard P, Moriau M, Bachy A, Malvaux P, De Meyer R. Meningococcal purpura: report of 19 patients treated with heparin. J Pediatr 1973;82:780-6.
18. Hattersley PG. Purpura fulminans. Complete recovery with intravenously administered heparin. Am J Dis Child 1970;120:467-71.
19. Kuppermann N, Inkelis SH, Saladino R. The role of heparin in the prevention of extremity and digit necrosis in meningococcal purpura fulminans. Pediatr Infect Dis J 1994;13:867-73.
20. Manios SG, Kanakoudi F, Maniati E. Fulminant meningococcemia. Heparin therapy and survival rate. Scand J Infect Dis 1971;3:127-33.
21. Fijnvandraat K, Derkx B, Peters M, Bijlmer R, Sturk A, Prins MH, et al. Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 1995;73:15-20.
22. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79:918-25.
23. Smith OP, White B, Vaughan D, Rafferty M, Claffey L, Lyons B, et al. Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 1997;350:1590-3.
24. Dreyfus M, Masterson M, David M, Rivard GE, Muller FM, Kreuz W, et al. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemost 1995;21:371-81.
25. Vigano D'Angelo S, Comp PC, Esmon CT, D'Angelo A. Relationship between protein C antigen and anticoagulant activity during oral anticoagulation and in selected disease states. J Clin Invest 1986;77:416-25.
26. Heyderman RS. Sepsis and intravascular thrombosis. Arch Dis Child 1993;68:621-3.
27. Burns ER, Zucker-Franklin D. Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells. Blood 1982;60: 1030-7.
28. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, et al. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982;307:1432-5.
29. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997;89:3097-103.
30. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-94.
31. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-84.
32. Amorsi EL, Ultmann JE. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 1966;45:139-46.
33. George JN, Berkowitz SD, Raskob GE. Platelet: acute thrombocytopenia. In: Hematology 1998: American Society of Hematology education program book. Miami (FL): American Society of Hematology; 1998. p. 371-83.
34. Moake J, Chintagumpala M, Turner N, McPherson P, Nolasco L, Steuber C, et al. Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood 1994;84:490-7.
35. Brailey LL, Brecher ME, Bandarenko N. Apheresis and the thrombotic thrombocytopenic purpura syndrome: current advances in diagnosis, pathophysiology, and management. Therapeutic Apheresis 1999;3:20-4.
36. Evans G, Llewelyn G, Luddington R, Baglin TP, Williamson LM. Solvent/detergent fresh frozen plasma as primary treatment of acute thrombotic thrombocytopenic purpura. Clin Lab Haematol 1999;21:119-23.
37. Fujsita M, Ito K, Koyama T, Shino K, Norioka M, Kashii S, et al. Large molecule fraction of plasma separated with polyethylene glycol in treatment of chronic relapsing thrombotic thrombocytopenic purpura. Am J Hematol 1995;49:149-52.